NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 4 filers reported holding NEKTAR THERAPEUTICS in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $639,704 | +11.2% | 1,074,049 | +7.4% | 0.00% | – |
| Q2 2023 | $575,218 | -32.0% | 1,000,032 | -16.9% | 0.00% | – |
| Q1 2023 | $845,918 | -72.8% | 1,203,469 | -12.6% | 0.00% | -100.0% |
| Q4 2022 | $3,110,194 | -28.5% | 1,376,192 | +1.2% | 0.00% | -50.0% |
| Q3 2022 | $4,350,000 | -12.6% | 1,359,279 | +3.8% | 0.00% | 0.0% |
| Q2 2022 | $4,977,000 | -2.6% | 1,309,657 | +38.2% | 0.00% | 0.0% |
| Q1 2022 | $5,109,000 | -59.4% | 947,937 | +1.8% | 0.00% | -50.0% |
| Q4 2021 | $12,576,000 | -22.9% | 930,867 | +2.6% | 0.00% | -20.0% |
| Q3 2021 | $16,301,000 | +6.6% | 907,573 | +1.8% | 0.01% | 0.0% |
| Q2 2021 | $15,295,000 | -12.2% | 891,265 | +2.3% | 0.01% | -16.7% |
| Q1 2021 | $17,429,000 | +2.4% | 871,415 | -13.0% | 0.01% | -14.3% |
| Q4 2020 | $17,024,000 | +7.8% | 1,001,361 | +5.2% | 0.01% | 0.0% |
| Q3 2020 | $15,793,000 | -26.6% | 951,932 | +2.5% | 0.01% | -36.4% |
| Q2 2020 | $21,507,000 | +44.0% | 928,597 | +11.0% | 0.01% | +22.2% |
| Q1 2020 | $14,936,000 | -11.7% | 836,712 | +6.8% | 0.01% | 0.0% |
| Q4 2019 | $16,909,000 | -11.6% | 783,357 | -25.4% | 0.01% | -18.2% |
| Q3 2019 | $19,125,000 | -28.4% | 1,049,925 | +39.9% | 0.01% | -31.2% |
| Q2 2019 | $26,709,000 | +9.9% | 750,656 | +3.8% | 0.02% | 0.0% |
| Q1 2019 | $24,298,000 | +5.3% | 723,146 | +3.0% | 0.02% | -11.1% |
| Q4 2018 | $23,083,000 | -44.0% | 702,245 | +3.8% | 0.02% | -33.3% |
| Q3 2018 | $41,231,000 | -4.8% | 676,358 | -23.7% | 0.03% | -15.6% |
| Q2 2018 | $43,298,000 | -64.8% | 886,694 | -23.4% | 0.03% | -66.7% |
| Q1 2018 | $123,075,000 | +156.8% | 1,158,240 | +44.3% | 0.10% | +152.6% |
| Q4 2017 | $47,924,000 | +183.9% | 802,474 | +14.1% | 0.04% | +153.3% |
| Q3 2017 | $16,879,000 | +31.8% | 703,282 | +7.4% | 0.02% | +25.0% |
| Q2 2017 | $12,803,000 | -13.9% | 654,847 | +3.4% | 0.01% | -20.0% |
| Q1 2017 | $14,871,000 | +110.1% | 633,597 | +9.8% | 0.02% | +87.5% |
| Q4 2016 | $7,078,000 | -20.0% | 576,813 | +12.0% | 0.01% | -20.0% |
| Q3 2016 | $8,848,000 | +33.3% | 514,978 | +10.4% | 0.01% | +25.0% |
| Q2 2016 | $6,636,000 | +5.4% | 466,288 | +1.8% | 0.01% | 0.0% |
| Q1 2016 | $6,298,000 | -18.5% | 458,008 | -0.1% | 0.01% | -20.0% |
| Q4 2015 | $7,723,000 | +72.1% | 458,288 | +12.0% | 0.01% | +42.9% |
| Q3 2015 | $4,487,000 | -35.2% | 409,353 | -26.1% | 0.01% | -30.0% |
| Q2 2015 | $6,928,000 | +75.3% | 553,780 | +54.2% | 0.01% | +66.7% |
| Q1 2015 | $3,952,000 | -32.9% | 359,183 | -5.5% | 0.01% | -33.3% |
| Q4 2014 | $5,890,000 | -3.6% | 379,985 | -25.0% | 0.01% | -10.0% |
| Q3 2014 | $6,113,000 | -3.9% | 506,453 | +2.0% | 0.01% | -9.1% |
| Q2 2014 | $6,363,000 | -1.7% | 496,309 | -7.0% | 0.01% | -8.3% |
| Q1 2014 | $6,470,000 | +32.1% | 533,813 | +23.7% | 0.01% | +33.3% |
| Q4 2013 | $4,897,000 | +0.6% | 431,398 | -7.3% | 0.01% | -10.0% |
| Q3 2013 | $4,868,000 | +37.0% | 465,385 | +56.7% | 0.01% | +25.0% |
| Q2 2013 | $3,553,000 | – | 297,006 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |